Alexion Pharma's rare blood disorder drug approved by U.S. FDA
The U.S. Food and Drug Administration (FDA) has recently approved Alexion Pharmaceuticals Inc's Ultomiris, a drug to treat rare blood disorder, nearly two months earlier than expected.
The IBES data from Refinitiv indicate that by 2022, the drug's sales might reach $1.66 billion.
Ultomiris has been approved to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare, acquired, life-threatening disorder in which red blood cells are destroyed prematurely.
Alexion already markets treatments for rare diseases, and its drug Soliris is approved to treat PNH.
To know more about the latest update on this treatment protocol and treating centers offering the same as well as
for getting your reports reviewed, post a query
